Vol 61, No 1 (2023)
Original paper
Published online: 2023-02-07

open access

Page views 2626
Article views/downloads 437
Get Citation

Connect on Social Media

Connect on Social Media

Periostin in ovarian carcinoma: from heterogeneity to prognostic value

Ludmila Lozneanu12, Irina-Draga Caruntu13, Cornelia Amalinei1, Mihaela Moscalu4, Bogdan Gafton56, Mihai Vasile Marinca56, Andreea Rusu1, Raluca Balan1, Simona-Eliza Giusca13
Pubmed: 36880681
Folia Histochem Cytobiol 2023;61(1):1-16.


Introduction. Periostin (POSTN), an extracellular matrix protein, is involved in tumor-associated extracellular matrix (ECM) remodeling. However, its potential value as a prognostic and/or predictive factor has not yet been confirmed. The present study aims to assess POSTN expression separately in tumor cells and stroma of different ovarian carcinoma (OC) histological types, and its relationship with clinicopathological features.

Material and methods. 102 cases of different histological OC subtypes were immunohistochemically investigated, for POSTN expression assessment in both epithelial tumor cells and tumor stroma. Statistical analysis was performed to correlate POSTN profile with clinicopathological characteristics, therapeutic response, and survival.

Results. POSTN expression in epithelial tumor cells was significantly correlated with POSTN expression in tumor stroma. The expression of POSTN in tumor cells was associated with histological type, tumor type (type I and II), tumor recurrence, progression-free survival (PFS), and overall survival (OS), whereas stromal POSTN expression was significantly correlated with age, histological type, tumor type, grade, and stage, residual disease, tumor recurrence, response to chemotherapy, and OS. Survival analysis revealed significant differences of PFS and OS in patients with high POSTN expression in tumor cells and negative stromal POSTN expression compared to patients with low POSTN expression in tumor cells and positive stromal POSTN expression (PFS: hazard ratio (HR) = 2.11, 95% confidence interval (CI): 1.33–3.37, P = 0.002; OS: HR = 1.78, 95% CI: 1.09–2.89, P = 0.019).

Conclusions. The comparative assessment of POSTN immunoexpression in two tumor compartments: in tumor cells and stroma, by use of different scoring systems revealed that higher stromal POSTN levels are evidently correlated with unfavorable clinical features and poorer prognosis, while POSTN expression in tumor cells seems to be associated with a better patient outcome.

Article available in PDF format

View PDF Download PDF file


  1. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017; 14(1): 9–32.
  2. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1): 7–33.
  3. Lukanović D, Kobal B, Černe K. Ovarian cancer: treatment and resistance to pharmacotherapy. Reproductive Medicine. 2022; 3(2): 127–140.
  4. Cheung AN, Ellenson LH, Gilks CB. Tumors of the Ovary. In: WHO Classification of Tumours Editorial Board. ed. Female Genital Tumours. 5th ed. International Agency for Research on Cancer, Lyon 2020: 32–37.
  5. Kurman R, Shih IM. The dualistic model of ovarian carcinogenesis. Am J Pathol. 2016; 186(4): 733–747.
  6. Govindarajan M, Wohlmuth C, Waas M, et al. High-throughput approaches for precision medicine in high-grade serous ovarian cancer. J Hematol Oncol. 2020; 13(1): 134.
  7. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005; 18 Suppl 2: S19–S32.
  8. Nik NN, Vang R, Shih IM, et al. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol. 2014; 9: 27–45.
  9. Qiu C, Lu N, Wang X, et al. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium. Gynecol Oncol. 2017; 147(3): 634–641.
  10. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum Pathol. 2011; 42(7): 918–931.
  11. Salazar C, Campbell IG, Gorringe KL. When Is "Type I" Ovarian Cancer Not "Type I"? Indications of an Out-Dated Dichotomy. Front Oncol. 2018; 8: 654.
  12. Kujawa KA, Zembala-Nożyńska E, Cortez AJ, et al. Fibronectin and periostin as prognostic markers in ovarian cancer. Cells. 2020; 9(1).
  13. Sterzyńska K, Kaźmierczak D, Klejewski A, et al. Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines. Int J Mol Sci. 2019; 20(16).
  14. Lu Z, Kamat K, Johnson BP, et al. Generation of a Fully Human scFv that binds Tumor-Specific Glycoforms. Sci Rep. 2019; 9(1): 5101.
  15. Kobierzycki C, Latkowski KJ, Dziegiel P. The usefulness of periostin determination in gynecology and obstetrics. Ginekol Pol. 2020; 91(6): 364–351.
  16. Chu L, Wang F, Zhang W, et al. Periostin secreted by carcinoma-associated fibroblasts promotes ovarian cancer cell platinum resistance through the PI3K/Akt signaling pathway. Technol Cancer Res Treat. 2020; 19: 1533033820977535.
  17. Yue H, Li W, Chen R, et al. Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer. Gynecol Oncol. 2021; 160(2): 530–538.
  18. Yamauchi N, Kanke Y, Saito K, et al. Stromal expression of cancer-associated fibroblast-related molecules, versican and lumican, is strongly associated with worse relapse-free and overall survival times in patients with esophageal squamous cell carcinoma. Oncol Lett. 2021; 21(6): 445.
  19. Ratajczak-Wielgomas K, Kmiecik A, Grzegrzołka J, et al. Prognostic significance of stromal periostin expression in non-small cell lung cancer. Int J Mol Sci. 2020; 21(19).
  20. Ratajczak-Wielgomas K, Kmiecik A, Dziegiel P. Role of periostin expression in non-small cell lung cancer: periostin silencing inhibits the migration and invasion of lung cancer cells via regulation of MMP-2 expression. Int J Mol Sci. 2022; 23(3).
  21. Oo KK, Kamolhan T, Soni A, et al. Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer. BMC Cancer. 2021; 21(1): 65.
  22. Cattrini C, Barboro P, Rubagotti A, et al. Integrative analysis of periostin in primary and advanced prostate cancer. Transl Oncol. 2020; 13(7): 100789.
  23. Ma H, Wang J, Zhao X, et al. Periostin Promotes Colorectal Tumorigenesis through Integrin-FAK-Src Pathway-Mediated YAP/TAZ Activation. Cell Rep. 2020; 30(3): 793–806.e6.
  24. Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999; 14(7): 1239–1249.
  25. Morra L, Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch. 2011; 459(5): 465–475.
  26. González-González L, Alonso J. Periostin: A Matricellular Protein With Multiple Functions in Cancer Development and Progression. Front Oncol. 2018; 8: 225.
  27. Takeshita S, Kikuno R, Tezuka K, et al. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993; 294 ( Pt 1)(Pt 1): 271–278.
  28. Hoersch S, Andrade-Navarro MA. Periostin shows increased evolutionary plasticity in its alternatively spliced region. BMC Evol Biol. 2010; 10: 30.
  29. Ji X, Chen D, Xu C, et al. Patterns of gene expression associated with BMP-2-induced osteoblast and adipocyte differentiation of mesenchymal progenitor cell 3T3-F442A. J Bone Miner Metab. 2000; 18(3): 132–139.
  30. Li P, Oparil S, Feng W, et al. Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. J Appl Physiol (1985). 2004; 97(4): 1550–8; discussion 1549.
  31. Takayama Go, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006; 118(1): 98–104.
  32. Norris RA, Moreno-Rodriguez RA, Sugi Y, et al. Periostin regulates atrioventricular valve maturation. Dev Biol. 2008; 316(2): 200–213.
  33. Kii I, Nishiyama T, Li M, et al. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem. 2010; 285(3): 2028–2039.
  34. Tanabe H, Takayama I, Nishiyama T, et al. Periostin associates with Notch1 precursor to maintain Notch1 expression under a stress condition in mouse cells. PLoS One. 2010; 5(8): e12234.
  35. Hwang EY, Jeong MiS, Park EK, et al. Structural characterization and interaction of periostin and bone morphogenetic protein for regulation of collagen cross-linking. Biochem Biophys Res Commun. 2014; 449(4): 425–431.
  36. Sasaki H, Yu CY, Dai M, et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat. 2003; 77(3): 245–252.
  37. Kudo Y, Ogawa I, Kitajima S, et al. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res. 2006; 66(14): 6928–6935.
  38. Kanno A, Satoh K, Masamune A, et al. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer. 2008; 122(12): 2707–2718.
  39. Sasaki H, Lo KM, Chen LB, et al. Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res. 2001; 92(8): 869–873.
  40. Zhu M, Fejzo MS, Anderson L, et al. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol. 2010; 119(2): 337–344.
  41. Sung PL, Jan YH, Lin SC, et al. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. Oncotarget. 2016; 7(4): 4036–4047.
  42. Yang T, Deng Z, Pan Z, et al. Prognostic value of periostin in multiple solid cancers: a systematic review with meta-analysis. J Cell Physiol. 2020; 235(3): 2800–2808.
  43. Ricciardelli C, Lokman NA, Ween MP, et al. WOMEN IN CANCER THEMATIC REVIEW: ovarian cancer-peritoneal cell interactions promote extracellular matrix processing. Endocr Relat Cancer. 2016; 23(11): T155–T168.
  44. Nuzzo PV, Buzzatti G, Ricci F, et al. Periostin: a novel prognostic and therapeutic target for genitourinary cancer? Clin Genitourin Cancer. 2014; 12(5): 301–311.
  45. Ryner L, Guan Y, Firestein R, et al. Upregulation of periostin and reactive stroma is associated with primary chemoresistance and predicts clinical outcomes in epithelial ovarian cancer. Clin Cancer Res. 2015; 21(13): 2941–2951.
  46. Gillan L, Matei D, Fishman DA, et al. Periostin secreted by epithelial ovarian carcinoma is a ligand for Alpha(V)Beta(3) and Alpha(V)Beta(5) integrins and promotes cell motility. Cancer Res. 2002; 62(18): 5358–5364.
  47. Ismail RS, Baldwin RL, Fang J, et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 2000; 60(23): 6744–6749.
  48. Choi KUn, Yun JS, Lee IlH, et al. Lysophosphatidic acid-induced expression of periostin in stromal cells: Prognoistic relevance of periostin expression in epithelial ovarian cancer. Int J Cancer. 2011; 128(2): 332–342.
  49. Karlan BY, Dering J, Walsh C, et al. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol. 2014; 132(2): 334–342.
  50. Abbott KL, Lim JM, Wells L, et al. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics. 2010; 10(3): 470–481.
  51. Tian Y, Yao Z, Roden RBS, et al. Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics. 2011; 11(24): 4677–4687.
  52. Zhu M, Saxton RE, Ramos L, et al. Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. Mol Cancer Ther. 2011; 10(8): 1500–1508.
  53. Tan TZ, Yang He, Ye J, et al. CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. Oncotarget. 2015; 6(41): 43843–43852.
  54. Tang M, Liu B, Bu X, et al. Cross-talk between ovarian cancer cells and macrophages through periostin promotes macrophage recruitment. Cancer Sci. 2018; 109(5): 1309–1318.
  55. Tumbarello DA, Temple J, Brenton JD. ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. Mol Cancer. 2012; 11: 36.
  56. Zhang Q, Wang C, Cliby WA. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecol Oncol. 2019; 152(2): 368–374.
  57. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreac-tive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987; 8(3): 138–140.
  58. Ratajczak-Wielgomas K, Dziegiel P. The role of periostin in neoplastic processes. Folia Histochem Cytobiol. 2015; 53(2): 120–132.
  59. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007; 104(40): 15858–15863.
  60. Izuhara K, Matsumoto H, Ohta S, et al. Recent developments regarding periostin in bronchial asthma. Allergol Int. 2015; 64 Suppl: S3–10.
  61. Dorn GW. Periostin and myocardial repair, regeneration, and recovery. N Engl J Med. 2007; 357(15): 1552–1554.
  62. Kühn B, del Monte F, Hajjar RJ, et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med. 2007; 13(8): 962–969.
  63. Shimazaki M, Nakamura K, Kii I, et al. Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med. 2008; 205(2): 295–303.
  64. Matei D, Graeber TG, Baldwin RL, et al. Gene expression in epithelial ovarian carcinoma. Oncogene. 2002; 21(41): 6289–6298.
  65. Lozneanu L. Periostin expressions in ovarian carcinoma. Virchows Archiv. 2016; 469 (suppl. 1): E-PS-14-010.
  66. Ansardamavandi A, Tafazzoli-Shadpour M. The functional cross talk between cancer cells and cancer associated fibroblasts from a cancer mechanics perspective. Biochim Biophys Acta Mol Cell Res. 2021; 1868(11): 119103.
  67. Liu AYi, Zheng H, Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. 2014; 37: 150–156.
  68. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1): 71–78.
  69. Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2015; 12(1): 1–4.
  70. Nuzzo PV, Rubagotti A, Zinoli L, et al. Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death. BMC Cancer. 2012; 12: 625.
  71. Bao S, Ouyang G, Bai X, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004; 5(4): 329–339.